Koraljka Gall-Trošelj
Epigenomics AG
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Koraljka Gall-Trošelj.
PLOS ONE | 2015
Ivana Grbeša; Maria J. Pajares; Elena Martínez-Terroba; Jackeline Agorreta; Ana-Matea Mikecin; Marta Larrayoz; Miguel Angel Idoate; Koraljka Gall-Trošelj; Ruben Pio; Luis M. Montuenga
Background Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are NAD+-dependent protein deacetylases involved in the regulation of key cancer-associated genes. In this study we evaluated the relevance of these deacetylases in lung cancer biology. Material and Methods Protein levels of SIRT1 and SIRT2 were determined in non-small cell lung cancer (NSCLC) cell lines and primary tumors from 105 patients. Changes in proliferation were assessed after SIRT1 and SIRT2 downregulation in lung cancer cell lines using siRNA-mediated technology or tenovin-1, a SIRT1 and SIRT2 inhibitor. Results High SIRT1 and SIRT2 protein levels were found in NSCLC cell lines compared with non-tumor lung epithelial cells. The expression of SIRT1 and SIRT2 proteins was also significantly higher in lung primary tumors than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear SIRT1 staining was observed in adenocarcinomas than in squamous cell carcinomas (P=0.033). Interestingly, in NSCLC patients, high SIRT1 and SIRT2 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high SIRT1 and SIRT2 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that SIRT1 and/or SIRT2 downregulation significantly decreased proliferation of NSCLC. Conclusions Our results support the hypothesis that SIRT1 and SIRT2 have a protumorigenic role in lung cancer, promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in NSCLC patients and may help to identify those NSCLC patients with high risk of recurrence that could benefit from adjuvant therapy after resection.
Journal of Molecular Medicine | 2008
Ivana Grbeša; Marino Marinkovic; Mirko Ivkić; Bozo Kruslin; Renata Novak-Kujundzic; Boris Pegan; Ozren Bogdanović; Vladimir Bedeković; Koraljka Gall-Trošelj
Imprinting analyses of IGF2 and H19, loss of heterozygosity (LOH) analyses of IGF2R and CTCF and Helicobacter pylori detection, were performed on 35 human laryngeal squamous cell carcinomas (LSCC). Forty-six percent of the tumors were heterozygous for IGF2, and 54% were informative for the H19. Biallelic expression of IGF2 was observed in 33% (5 out of 15) of the tumors and in 27% (4 out of 15) of adjacent non-tumorous laryngeal tissues. H19 loss of imprinting (LOI) was observed in 24% (4 out of 17) of the tumors. For IGF2R and CTCF, 71% (25 out of 35) and 50% (17/34), respectively, of the samples were heterozygous, and LOH was detected in 12% (3 out of 25) and 6% (1 out of 17), respectively, of the tumors. H. pylori was found in 26% (9/35) of these tumors. Among them, four were informative for the imprinting analysis. The presence of H. pylori had no effect on IGF2/H19 imprinting. Only the H. pylori detection was further broadened with an additional 47 laryngeal tumors, resulting in a total final positivity of close to 16% (13 out of 82). This study represents the largest comprehensive IGF2/H19 imprinting study done to date on well-defined samples of human laryngeal carcinomas and corresponding non-tumorous tissue. For the first time, the analyses of IGF2/H19 imprinting have been broadened with LOH analyses of IGF2R and CTCF, with both of these genes acting as modulators of IGF2 and H19 activity. Although there were indications that H. pylori may be present in LSCC, we are the first to show its presence in LSCC by two direct techniques: Giemsa staining and nested-PCR.
Cancer Letters | 2006
Ivana Grbeša; Mirko Ivkić; Boris Pegan; Koraljka Gall-Trošelj
Acta Biochimica Polonica | 2010
Ana Cipak; Suzana Borović; Morana Jaganjac; Nikolaus Bresgen; Iva Kirac; Ivana Grbeša; Lidija Mrakovcic; Marina Cindrić; Mira Scukanec-Spoljar; Koraljka Gall-Trošelj; Marijana Ćorić; Peter Eckl; Neven Zarkovic
PLOS ONE | 2015
Ivana Grbeša; Maria J. Pajares; Elena Martínez-Terroba; Jackeline Agorreta; Ana-Matea Mikecin; Marta Larrayoz; Miguel Angel Idoate; Koraljka Gall-Trošelj; Ruben Pio; Luis M. Montuenga
Archive | 2009
Ivana Grbeša; Sandra Kolundžija; Renata Novak Kujundžić; Koraljka Gall-Trošelj
Metode u molekularnoj biologiji | 2008
Maja Čretnik; Ivana Grbeša; Sonja Levanat; Koraljka Gall-Trošelj
Congress of the Croatian Society of Biochemistry and Molecular Biology with international participation (HDBMB 2008) : book of abstracts | 2008
Irena Martin-Kleiner; M. Radetić; Ivana Grbeša; Domagoj Parazajder; Miljenko Kovačić; Martina Radetić; Koraljka Gall-Trošelj
Archive | 2007
Maja Čretnik; Ivana Grbeša; Sonja Levanat; Koraljka Gall-Trošelj
Archive | 2007
Ivana Grbeša; Koraljka Gall-Trošelj